Cellulitis & Erysipelas
Summary
Cellulitis and erysipelas are common acute bacterial skin and soft tissue infections (SSTIs). Cellulitis involves the deeper dermis and subcutaneous fat with ill-defined spreading margins, while erysipelas is more superficial, involving the upper dermis and lymphatics with characteristically well-demarcated, raised edges. Both typically present with erythema, warmth, swelling, and tenderness, often with systemic symptoms. Group A Streptococcus (Streptococcus pyogenes) is the most common causative organism, followed by Staphylococcus aureus. Most cases respond to oral antibiotics (flucloxacillin), but severe infections require IV therapy. Critically, cellulitis must be differentiated from necrotising fasciitis, a surgical emergency.
Key Facts
- Definition: Acute spreading bacterial infection of skin and subcutaneous tissue
- Incidence: 200 per 100,000 person-years; 2-4% of emergency department presentations
- Most common organisms: Streptococcus pyogenes (Group A Strep) and Staphylococcus aureus
- Most common site: Lower limb (70-80%)
- Key differentiator: Erysipelas has raised, sharply demarcated edges; cellulitis has ill-defined margins
- First-line treatment: Flucloxacillin 500mg-1g QDS orally (or IV if severe)
- Critical mimic: Necrotising fasciitis (pain out of proportion, rapid spread)
Clinical Pearls
Eron Classification: Use this to guide oral vs IV antibiotics and disposition. Class I-II can be managed as outpatients; Class III-IV need admission.
Draw the Line: Mark the leading edge of erythema with permanent marker and timestamp it. This is the most reliable way to track progression or response to treatment.
Treat the Portal: Most lower limb cellulitis occurs due to tinea pedis (athlete's foot) or leg ulcers providing entry for bacteria. Always check between the toes and treat any interdigital maceration.
Why This Matters Clinically
Cellulitis is the 4th most common reason for emergency hospital admission for infection. While most cases are straightforward, failure to recognise necrotising fasciitis leads to delayed surgery and high mortality (30-40%). Recurrent cellulitis occurs in 20-30% of patients, often due to untreated risk factors like lymphoedema or tinea pedis.
Incidence & Prevalence
- Incidence: 200 per 100,000 person-years
- Hospital admissions: 6.5 per 1000 admissions in UK
- Recurrence rate: 20-30% within 3 years
- Trend: Increasing with ageing population and obesity
Demographics
| Factor | Details |
|---|---|
| Age | Peak incidence in adults over 65 |
| Sex | Equal or slight male predominance |
| Site | Lower limb 70-80%; face, arm, other 20-30% |
| Seasonal | Slight summer increase |
Risk Factors
Non-Modifiable:
- Previous cellulitis (strongest risk factor — OR 10-20)
- Lymphoedema / venous insufficiency
- Surgical disruption of lymphatics (e.g., mastectomy, saphenous vein harvest)
Modifiable:
| Risk Factor | Relative Risk |
|---|---|
| Tinea pedis (athlete's foot) | 2-3x |
| Obesity | 2-4x |
| Leg ulcers | 2-3x |
| Diabetes mellitus | 1.5-2x |
| Peripheral vascular disease | 2x |
| Immunosuppression | 2-3x |
| IV drug use | 3-5x (especially MRSA) |
Mechanism
Step 1: Breach in Skin Barrier
- Trauma (even minor), insect bites, surgeryincisions, or interdigital tinea pedis
- Fissures between toes are most common portal for lower limb cellulitis
- Leg ulcers, eczema, and dermatitis also provide entry points
Step 2: Bacterial Invasion
- Streptococcus pyogenes (GAS) or Staphylococcus aureus enter dermis
- Streptococci produce enzymes (streptokinase, hyaluronidase) aiding spread
- Staphylococci tend to cause more localised infection with abscess formation
Step 3: Inflammatory Response
- Host immune response causes erythema, oedema, warmth
- Cytokine release leads to systemic symptoms (fever, malaise)
- Lymphangitis may occur (red streaking toward lymph nodes)
Step 4: Spread or Resolution
- If untreated, infection spreads horizontally through skin layers
- Risk of bacteraemia, abscess formation, or rarely necrotising fasciitis
- With treatment, resolution typically within 5-10 days
Classification
Cellulitis vs Erysipelas:
| Feature | Cellulitis | Erysipelas |
|---|---|---|
| Depth | Deeper dermis + subcutaneous fat | Upper dermis + superficial lymphatics |
| Edge | Ill-defined, diffuse | Well-demarcated, raised (peau d'orange) |
| Surface | Flat | Raised, indurated |
| Organism | S. aureus and/or GAS | Predominantly GAS |
| Systemic symptoms | Variable | Often prominent early |
| Site | Most common: lower leg | Face and lower limbs |
Eron Classification (Severity):
| Class | Features | Management |
|---|---|---|
| I | No systemic toxicity, no comorbidities | Outpatient oral antibiotics |
| II | Systemic toxicity OR unstable comorbidity | Outpatient or brief observation |
| III | Significant systemic upset, partial treatment failure | Inpatient IV antibiotics |
| IV | Sepsis, necrotising fasciitis | ICU, surgical debridement |
Anatomical Considerations
- Lower limb predilection due to dependent oedema, venous stasis, and proximity to tinea pedis
- Facial cellulitis: Risk of spread to periorbital or orbital structures, cavernous sinus
- Perineal cellulitis: Consider Fournier's gangrene (necrotising fasciitis)
Symptoms
Typical Presentation:
Associated Symptoms:
Atypical Presentations:
Signs
Local Signs:
Systemic Signs:
Portal of Entry:
Red Flags
[!CAUTION] Red Flags — URGENT surgical review required if:
- Pain out of proportion to clinical signs (suggests necrotising fasciitis)
- Rapid progression of erythema despite antibiotics (greater than 1cm/hour)
- Crepitus on palpation (gas in tissues — NF or gas gangrene)
- Bullae with purple/dusky discoloration
- Skin necrosis
- Haemodynamic instability (sepsis)
- Immunocompromise with severe presentation
Structured Approach
General:
- Observations: Temperature, HR, BP, RR, SpO2 (sepsis screening)
- General appearance: Ill/toxic vs well
- NEWS score if in hospital setting
Local Skin Examination:
- Inspect: Define extent of erythema, demarcation, surface changes
- Palpate: Warmth, tenderness, oedema (pitting?), crepitus
- Mark the edge: Use permanent marker with date/time
- Measure: Size of area affected
Portal of Entry Search:
- Interdigital spaces: Look for tinea pedis (maceration, scaling)
- Leg ulcers: Venous or arterial
- Wounds, insect bites, abrasions
- Postoperative incisions (if recent surgery)
Regional Examination:
- Lymph nodes: Inguinal (lower limb), axillary (upper limb), cervical (facial)
- Lymphangitis: Red streaking toward lymph nodes
Special Tests
| Test | Technique | Positive Finding | Clinical Significance |
|---|---|---|---|
| NEWS/qSOFA | Vital signs scoring | Score ≥2 | Sepsis — escalate care |
| Finger test | Pass finger along skin under local anaesthesia | Lack of bleeding, dishwater pus | Suggests necrotising fasciitis |
| Elevation | Raise affected limb | Rapid improvement suggests venous aetiology, not infection | Helps differentiate stasis |
| Drawing the line | Mark erythema edge, review in 24-48h | Expansion beyond line | Treatment failure |
First-Line (Bedside)
- Observations — Sepsis screen (NEWS, qSOFA)
- Capillary blood glucose — Exclude/assess diabetes
- Examination of interdigital spaces — Tinea pedis
Laboratory Tests
| Test | Expected Finding | Purpose |
|---|---|---|
| FBC | Leukocytosis (WCC greater than 10 × 10⁹/L) | Assess inflammatory response |
| CRP | Elevated | Infection marker; useful for monitoring |
| U&Es | Usually normal; may show AKI in sepsis | Baseline, hydration status |
| Blood cultures | Positive in 2-5% (low yield) | Consider if febrile, severe, or immunocompromised |
| Glucose / HbA1c | May reveal undiagnosed diabetes | Modifiable risk factor |
| Lactate | Elevated in sepsis | Sepsis severity marker |
Imaging
| Modality | Findings | Indication |
|---|---|---|
| Ultrasound | Fluid collection / abscess | If fluctuance suspected; guide drainage |
| Plain X-ray | Soft tissue gas (clostridial infection, NF) | If crepitus present |
| CT with contrast | Fat stranding, gas tracking, fascial thickening | If necrotising fasciitis suspected |
| MRI | Fascial enhancement | Most sensitive for NF; may delay surgery — clinical diagnosis preferred |
Diagnostic Criteria
Clinical Diagnosis (No specific criteria required):
- Typical clinical features (erythema, warmth, swelling, tenderness) ± systemic symptoms
- Blood tests are supportive but not diagnostic
- Cultures often negative (organisms in tissue, not blood)
Management Algorithm
Conservative Management
- Mark erythema edge — With permanent marker and time; review in 24-48h
- Limb elevation — Reduces oedema, aids resolution
- Treat portal of entry — Antifungal for tinea pedis (terbinafine cream, nystatin)
- Analgesia — Paracetamol ± NSAIDs
- Compression stockings — After acute episode resolves if venous insufficiency
Medical Management
Oral Antibiotics (Eron Class I-II):
| Drug | Dose | Duration | Notes |
|---|---|---|---|
| Flucloxacillin | 500mg-1g QDS | 5-7 days | First-line |
| Co-amoxiclav | 625mg TDS | 5-7 days | Alternative |
| Clarithromycin | 500mg BD | 5-7 days | Penicillin allergy |
| Doxycycline | 200mg stat then 100mg BD | 7 days | Penicillin allergy |
IV Antibiotics (Eron Class III-IV):
| Drug | Dose | Indication |
|---|---|---|
| Flucloxacillin IV | 1-2g QDS | Severe cellulitis |
| Benzylpenicillin IV | 1.2g QDS | Add if streptococcal suspected |
| Clindamycin IV | 600mg-1.2g TDS | Penicillin allergy; or add in NF (toxin suppression) |
| Vancomycin IV | Per levels | MRSA suspected (IVDU, previous MRSA) |
IV to Oral Switch:
- Improvement in local signs
- Systemically well, afebrile for 24-48 hours
- Able to tolerate oral medication
Surgical Management
Indications:
- Abscess requiring drainage (incision and drainage)
- Necrotising fasciitis (emergency surgical debridement)
- Non-responding cellulitis with underlying foreign body
Disposition
- Discharge with oral antibiotics: Eron Class I-II, well, reliable follow-up
- Admit for IV antibiotics: Eron Class III-IV, sepsis features, failure of oral therapy
- Follow-up: 48-72 hours review (GP or clinic) to assess response to treatment
Immediate (Hours)
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Sepsis | 5-10% of admissions | Fever, tachycardia, hypotension | IV antibiotics, fluids, sepsis bundle |
| Progression to necrotising fasciitis | Rare (less than 1%) | Severe pain, rapid spread, crepitus | Emergency surgical debridement |
Early (Days-Weeks)
- Abscess formation: Fluctuance develops; requires drainage
- Treatment failure: Non-response after 48-72h — consider MRSA, abscess, wrong diagnosis
- Bacteraemia: Positive blood cultures (2-5%); may need prolonged IV therapy
- Deep vein thrombosis: Leg swelling may mask or predispose; consider if persistent swelling
Late (Weeks-Months)
- Recurrence: 20-30% within 3 years; often at same site
- Post-cellulitis syndrome: Persistent oedema and hyperpigmentation; not infection
- Secondary lymphoedema: Damage to lymphatics leads to chronic swelling
- Chronic ulceration: Especially in patients with venous insufficiency
Natural History
- Without treatment: Progressive spread, systemic sepsis, potential for necrotising fasciitis
- With treatment: Resolution within 5-10 days; most respond to oral antibiotics
Outcomes with Treatment
| Variable | Outcome |
|---|---|
| Response to oral antibiotics | 70-80% |
| Need for IV step-up | 20-30% |
| Hospital admission rate | 15-20% of all presentations |
| Mortality | less than 1% (higher in NF: 20-40%) |
| Recurrence | 20-30% (higher if lymphoedema) |
Prognostic Factors
Good Prognosis:
- Young, fit patient
- First episode
- No comorbidities
- Portal of entry addressed (tinea treated)
- Early presentation
Poor Prognosis:
- Diabetes mellitus
- Immunosuppression
- Lymphoedema
- Prior cellulitis at same site
- Delay in treatment
- Advancing age
Key Guidelines
- NICE NG141 (2019) — Cellulitis and erysipelas: antimicrobial prescribing. Recommends flucloxacillin first-line; 5-7 day course. NICE NG141
- CREST Guidelines (2005) — Guidelines on the management of cellulitis in adults. Early UK regional guidance, widely influential. CREST
- PHE/NICE Antimicrobial Prescribing (2019) — Antibiotic choice based on local resistance patterns. PHE
Landmark Trials
PATCH I Trial (Thomas et al., 2011) — Prophylactic antibiotics for recurrent cellulitis
- 274 patients with recurrent cellulitis randomised to penicillin V or placebo
- Key finding: Penicillin reduced recurrence by 45% while on treatment
- Clinical Impact: Supports prophylactic antibiotics in recurrent cases
PATCH II Trial (2017) — Follow-up of PATCH I
- Extended analysis showed effect wanes after stopping prophylaxis
- Clinical Impact: Raises question of appropriate duration of prophylaxis
Kilburn et al. (2010) — Eron classification validation
- Demonstrated that Eron classification predicts need for hospitalisation and IV therapy
- Clinical Impact: Widely adopted for severity stratification
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Flucloxacillin first-line | 1a | NICE systematic review |
| 5-7 day antibiotic course | 1b | RCTs |
| Limb elevation | 2b | Observational evidence |
| Prophylactic penicillin for recurrence | 1b | PATCH Trial |
What is Cellulitis?
Cellulitis is a skin infection caused by bacteria that have got under the skin, usually through a small cut, insect bite, or cracked skin (like athlete's foot between your toes). The skin becomes red, swollen, warm, and painful. It can spread if not treated and sometimes makes you feel generally unwell with a fever.
Is it serious?
For most people, cellulitis is uncomfortable but treatable with antibiotics. However, if it spreads quickly, causes severe pain, or you become very unwell, it can be a sign of a more serious infection that needs urgent hospital treatment.
How is it treated?
- Antibiotics: Most people take tablets (usually flucloxacillin) for 5-7 days. If the infection is more severe, you may need antibiotics through a drip in hospital.
- Resting the area: Keeping the affected limb raised (e.g., leg on a stool) helps reduce swelling.
- Treating the cause: If you have athlete's foot or a skin break that let the bacteria in, this should also be treated to prevent recurrence.
- Marking the edge: The doctor may draw around the red area with a pen to track whether it's getting better or worse.
What to expect
- The area may look worse initially before improving (redness may deepen as inflammation resolves)
- Improvement is usually seen within 2-3 days of starting antibiotics
- Full resolution takes 5-10 days
- There may be some residual discolouration or swelling for weeks
When to seek help
Go back to your doctor or seek urgent medical attention if:
- The redness is spreading rapidly (faster than you can mark it)
- The pain is getting much worse despite painkillers
- You develop new blisters, blackish discolouration, or the skin looks dusky
- You feel increasingly unwell (fever, shivering, confusion)
- The antibiotics aren't helping after 2-3 days
Primary Guidelines
- National Institute for Health and Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing (NG141). 2019. NICE NG141
- Public Health England. Management of infection guidance for primary care. 2019.
Key Trials
- Thomas KS, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695-1703. PMID: 23635049
- Thomas KS, et al. Penicillin prophylaxis for recurrent cellulitis: the PATCH trial follow-up. Br J Dermatol. 2017;176(5):1225-1232. PMID: 27943246
- Eron LJ, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1:i3-17. PMID: 14662806
- Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA. 2016;316(3):325-337. PMID: 27434444
Further Resources
- NHS Cellulitis: nhs.uk/conditions/cellulitis
- DermNet NZ Cellulitis: dermnetnz.org/topics/cellulitis
- British Association of Dermatologists: bad.org.uk
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always seek urgent medical advice if necrotising fasciitis is suspected.